Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies, Febit Ink Co-marketing Deal

NEW YORK (GenomeWeb News) – Life Technologies and Febit jointly announced today that they have signed a co-marketing deal, under which the firms will offer Febit's HybSelect sequence capture technology with Life Tech's SOLiD sequencing system.

The firms said that the alliance is aimed at researchers conducting targeted resequencing studies.

Febit's HybSelect system combines microarray-based enrichment with microfluidics on an automated instrument. The system's eight segregated arrays within a single microfluidic biochip enable parallel, hands-off processing of samples, the firms said.

In addition, the companies said that Febit will add several SOLiD sequencing and real-time PCR systems to its Genomic Services Facility at Heidelberg. Febit said that it is now a member of both the SOLiD System and TaqMan Service Provider Programs.

"Our next-generation sequencing facility will take the lead in targeted sequencing of more than 1,000 samples per week," Peer Staehler, chief scientific officer of Febit, said in a statement. He added that the company has "the capability to go from tailor-made target sequence capture to sequencing results in days, both for customers and our own internal development programs."

Last week, Life Technologies and Agilent announced a co-marketing agreement that combines Agilent's SureSelect Target Enrichment System with the SOLiD system.